These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1851386)

  • 1. Combination chemotherapy and interferon alpha 2b in the treatment of advanced non-small-cell lung cancer. The Italian Lung Cancer Task Force (FONICAP).
    Ardizzoni A; Rosso R; Salvati F; Scagliotti G; Soresi E; Ferrara G; Pennucci C; Baldini E; Cruciani AR; Antilli A
    Am J Clin Oncol; 1991 Apr; 14(2):120-3. PubMed ID: 1851386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report. The Italian Lung Cancer Task Force.
    Ardizzoni A; Salvati F; Rosso R; Bruzzi P; Rubagotti A; Pennucci MC; Mariani GL; De Marinis F; Pallotta G; Antilli A
    Cancer; 1993 Nov; 72(10):2929-35. PubMed ID: 8221559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
    Parra HS; Tixi L; Latteri F; Bretti S; Alloisio M; Gravina A; Lionetto R; Bruzzi P; Dani C; Rosso R; Cosso M; Balzarini L; Santoro A; Ardizzoni A
    Cancer; 2001 Aug; 92(3):650-6. PubMed ID: 11505411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
    Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of chemotherapy and recombinant interferon-alpha in advanced non-small cell lung cancer.
    Hastürk S; Kurt B; Kocabaş A; Nadirler F; Orüc O
    Cancer Lett; 1997 Jan; 112(1):17-22. PubMed ID: 9029165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study.
    Vokes EE; Haraf DJ; Hoffman PC
    Cancer Chemother Pharmacol; 1993; 33(3):203-9. PubMed ID: 8269601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
    Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
    Hussain M; Benedetti J; Smith RE; Rodriguez GI; Schuller D; Ensley J
    Cancer; 1995 Oct; 76(7):1233-7. PubMed ID: 8630903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study.
    Kataja V; Yap A
    Eur J Cancer; 1995; 31A(1):35-40. PubMed ID: 7695976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of intraperitoneal interferon-alpha 2b and intravenous cis-platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study.
    Moore DH; Valea F; Walton LA; Soper J; Clarke-Pearson D; Fowler WC
    Gynecol Oncol; 1995 Nov; 59(2):267-72. PubMed ID: 7590485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant alpha-interferon and chemotherapy in advanced squamous cell carcinoma of the head and neck.
    Benasso M; Merlano M; Blengio F; Cavallari M; Rosso R; Toma S
    Am J Clin Oncol; 1993 Dec; 16(6):465-8. PubMed ID: 8256758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer.
    Umsawasdi T; Valdivieso M; Booser DJ; Barkley HT; Ewer M; MacKay B; Dhingra HM; Murphy WK; Spitzer G; Chiuten DF
    Cancer; 1989 Nov; 64(10):1995-2000. PubMed ID: 2553235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
    Tummarello D; Graziano F; Isidori P; Santo A; Cetto G; Fedeli A; Rossi G; Cellerino R
    Cancer; 1996 Jun; 77(11):2251-7. PubMed ID: 8635092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
    Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
    Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of days 1 and 8 cisplatin and recombinant alpha-2B interferon in advanced non-small cell lung cancer.
    Rosell R; Carles J; Ariza A; Moreno I; Ribelles N; Solano V; Pellicer I; Barnadas A; Abad A
    Cancer; 1991 May; 67(10):2448-53. PubMed ID: 1707745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer.
    Cartei G; Cartei F; Cantone A; Causarano D; Genco G; Tobaldin A; Interlandi G; Giraldi T
    J Natl Cancer Inst; 1993 May; 85(10):794-800. PubMed ID: 8387607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer.
    Murray N; Coppin C; Coldman A; Pater J; Rapp E
    J Clin Oncol; 1994 Nov; 12(11):2333-9. PubMed ID: 7964949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
    Mantovani G; Macciò A; Mulas C; Massa E; Madeddu C; Mura L; Contu P; Versace R
    Oncol Rep; 2002; 9(3):661-70. PubMed ID: 11956647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.